President Biden will issue a determination that gives the Department of Health and Human Services (HHS) broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under the Defense Production Act, the White House announced today. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.